Fusarium spp. are moulds ubiquitously distributed in nature and only occasionally pathogenic for humans. Species of the Fusarium solani complex are the predominant keratitis-inducing pathogens, because they are endowed with proper virulence factors. These fungi can adhere to the cornea creating a biofilm and, with the help of enzymes and cytotoxins, penetrate the cornea. Whereas an intact cornea is hardly able to be invaded by Fusarium spp. in spite of appropriate virulence factors, these opportunistic fungi may profit from predisposing conditions, for example mechanical injuries. This can lead to a progressive course of corneal infection and may finally affect the whole eye up to the need for enucleation. Here, we present and discuss the clinical, microbiological and histopathological aspects of a particular case due to Fusarium tonkinense of the Fusarium solani complex with severe consequences in a patient without any obvious predisposing factors. A broad portfolio of antifungal agents was applied, both topically and systemically as well as two penetrating keratoplasties were performed. The exact determination of the etiologic agent of the fungal infection proved likewise to be very challenging.
Seven new antimycotics are presented that are at different points of development or approval. These substances are mainly first-in-class drugs. They are primarily developed for systemic administration. However, with the support of a pharmacist, the intravenous formulation may be used as eyedrops. In this short review, the activities of the substances against various fungal infections are described. After unsuccessful conventional therapy of fungal eye infections, one of these new substances might be suitable to cure the mycosis.
Die Publikation von Röck et al. suggeriert, dass Cefuroxim am Ende einer Kataract-OP die Endophthalmitisrate senken könne [1]. Dabei handelt es sich um eine sog. Intertime-Tend-Study, wie sie auch von anderen Autoren als Scheinbeweis verwendet worden ist [2], [3]. Beweisen kann man aber mit dem Vergleich zweier Perioden nur, dass man im Zeitraum B (meist jüngeren Datums) besser geworden ist als im Zeitraum A (meist früher). Das kann an vielen Faktoren liegen z. B. bessere Operateure als früher, Zunahme an Erfahrung desselben Operateurs, andere (verbesserte) Operationstechnik u. s. w. Wenn man aber den Nachweis eines Einflusses von Cefuroxim auf die Endophthalmitisrate erbringen möchte, muss man eine prospektive, randomisierte, zeitgleiche Studie durchführen – wie es die ESCRS-Studie beabsichtigte. Diese konnte den Beweis allerdings nicht erbringen, da viele Mängel und offene Fragen nicht geklärt wurden [4], [5].